ArticleWorld journal of clinical oncology2026
Development and internal validation of an immune-based prognostic modeling of early-onset colorectal cancer
Article in World journal of clinical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundEarly-onset colorectal cancer (EOCRC) is an aggressive malignancy with rising incidence and poor prognosis in young adults. Circulating immune cells may hold prognostic value, yet their role in EOCRC outcomes remains unclear.
aimTo develop machine learning-based prognostic models using peripheral immune markers in a retrospective cohort of EOCRC patients.
methodsA cohort of 123 EOCRC patients undergoing radical resection, from January 2017 to December 2020 was included. Data were extracted from medical records with a follow-up till July 2025. Blood samples were processed for flow cytometry to assess immune markers.
resultsUnivariable screening identified disease stage and CD16+CD56+ natural killer (NK) cell percentage as top predictors. A parsimonious Cox model integrating stage and high NK cells outperformed random survival forests (concordance index 0.693
conclusionThis two-factor model offers moderate accuracy for personalized EOCRC risk stratification, highlighting systemic NK cell dysfunction as a potential immunotherapy target. External validation is warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.